Celgene (NASDAQ:CELG) was downgraded by equities researchers at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday. They presently have a $121.00 price objective on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price target suggests a potential upside of 15.51% from the company’s current price.
Several other equities analysts also recently issued reports on CELG. Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a research report on Tuesday, August 29th. BTIG Research reiterated a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. Cowen reiterated a “buy” rating and set a $150.00 price objective on shares of Celgene in a research report on Tuesday, September 12th. Bank of America reiterated a “buy” rating on shares of Celgene in a research report on Wednesday, September 13th. Finally, Royal Bank of Canada began coverage on Celgene in a research report on Thursday, September 14th. They set a “top pick” rating and a $176.00 price objective for the company. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $132.63.
Celgene (CELG) opened at $104.75 on Wednesday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a market capitalization of $82,243.13, a P/E ratio of 24.88, a price-to-earnings-growth ratio of 0.81 and a beta of 1.78.
Large investors have recently made changes to their positions in the business. Thompson Davis & CO. Inc. grew its holdings in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI grew its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares in the last quarter. Robecosam AG purchased a new position in shares of Celgene during the 3rd quarter valued at $114,000. Guidant Wealth Advisors purchased a new position in shares of Celgene during the 3rd quarter valued at $119,000. Finally, Capital Bank & Trust Co grew its holdings in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 517 shares in the last quarter. 79.74% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Sanford C. Bernstein Downgrades Celgene (CELG) to Market Perform” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.com-unik.info/2017/12/29/sanford-c-bernstein-downgrades-celgene-celg-to-market-perform.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.